Company Profile:
At Verastem Oncology, we address urgent needs of patients living with cancers driven by RAS/MAPK pathway mutations, a key driver of tumor growth and treatment resistance. FDA approval of AVMAPKI FAKZYNJA CO-PACK delivered the first therapy for women living with recurrent KRAS-mutated low-grade serous ovarian cancer, a rare cancer with significant unmet need. We’ve launched this novel/novel combination therapy in the U.S. and are exploring pathways for Europe and Japan. We continue to advance our pipeline of drugs to help block cancer cell survival, inhibit tumor growth, and overcome treatment resistance. This is an exciting opportunity to shape the future of cancer care and make a meaningful impact in the lives of patients.
Summary:
We are looking for an experienced, in-house Paralegal/Contract Manager to join our Legal team as part of a fast-growing, fully integrated biotech company. The role includes substantive, independent paralegal work, along with responsibility to support, and coordinate with the owner of and cross-functional partners, the Agiloft contract management system that underpins the contracting work led by the Legal function. The position will be responsible for managing the contract lifecycle and owns system and vendor relationships that allow a lean department to operate at a highly efficient and productive scale. The role needs an experienced in-house paralegal with pharmaceutical/biotech company experience, an individual contributor looking for a high impact role with significant autonomy and cross-functional visibility.
Job Duties and Responsibilities:
Provide support for the administration of the Agiloft contract management system, including intake, triage, routing and version control, execution of finalized agreements through the electronic signature platform, and coordination with the internal business owners of the contract and counterparties, and post-execution maintenance of agreements.
Essential/Required Qualifications

Verastem Oncology (Nasdaq: VSTM) (Verastem, Inc.) is a biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of patients diagnosed with RAS/MAPK pathway-driven cancers. Our pipeline is focused on novel small molecule drugs that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, including RAF/MEK inhibition, FAK inhibition and KRAS G12D inhibition.
Pursuing unexplored pathways demands that we’re purposeful in everything we do. And it’s an endeavor that’s only possible with an experienced team of employees and partners dedicated to a singular purpose: changing and improving the way cancer is treated by delivering novel therapies that address areas of high unmet need in RAS/MAPK pathway-driven cancers. At Verastem Oncology, it takes our diversity of backgrounds, expertise, perspectives, and skills to find the answers that patients need, but don’t have—yet. To join our team or for more information, please visit www.verastem.com.
X/Twitter: @VerastemOncolog